Abode Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 11-12-2024
- Paid Up Capital ₹ 0.10 M
as on 11-12-2024
- Company Age 16 Year, 8 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 2.98 M
as on 11-12-2024
- Revenue -33.28%
(FY 2019)
- Profit -75.29%
(FY 2019)
- Ebitda -165.19%
(FY 2019)
- Net Worth 3.86%
(FY 2019)
- Total Assets 1.84%
(FY 2019)
About Abode Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.98 M.
Prakash Nayaneni and Prakash Naineni serve as directors at the Company.
- CIN/LLPIN
U24232TG2008PTC058838
- Company No.
058838
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Apr 2008
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media
What products or services does Abode Drugs Private Limited offer?
Abode Drugs Private Limited offers a wide range of products and services, including Flavours & Aromatics, Anti Caking Agents.
Who are the key members and board of directors at Abode Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prakash Naineni  | Director | 25-Apr-2008 | Current |
| Prakash Nayaneni | Director | 25-Apr-2008 | Current |
Financial Performance of Abode Drugs.
Abode Drugs Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 33.28% decrease. The company also saw a substantial fall in profitability, with a 75.29% decrease in profit. The company's net worth moved up by a moderate rise of 3.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Abode Drugs?
In 2016, Abode Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Abode Biotec India Private LimitedActive 10 years 5 monthsPrakash Nayaneni and Prakash Naineni are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 16 Feb 2021 | ₹1.54 M | Open |
Hdfc Bank Limited Creation Date: 25 Jan 2021 | ₹1.44 M | Open |
How Many Employees Work at Abode Drugs?
Abode Drugs has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Abode Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Abode Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
